XERIS BIOPHARMA HOLDINGS, INC. Amortization of Intangible Assets
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Amortization of Intangible Assets of $2.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $2.71M, a 0.00% change year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $2.71M, a 0.00% change year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $2.71M, a 0.00% change year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $2.71M, a 0.00% change year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for fiscal 2025 was $10.84M, a 0.00% change from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for fiscal 2024 was $10.84M, a 0.00% change from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for fiscal 2023 was $10.84M, a 0.00% change from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of intangible assets for fiscal 2022 was $10.84M, a 1871.45% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.71M 10-Q · filed 2026-08-06 | $5.42M 10-Q · filed 2026-08-06 | $8.13M derived: sum of 3 quarters · filed 2026-08-06 | $10.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $2.71M 10-Q · filed 2026-05-07 | $5.42M derived: sum of 2 quarters · filed 2026-05-07 | $8.13M derived: sum of 3 quarters · filed 2026-05-07 | $10.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.42M derived: sum of 2 quarters · filed 2026-03-02 | $8.13M derived: sum of 3 quarters · filed 2026-08-06 | $10.84M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $2.71M 10-Q · filed 2025-11-06 | $5.42M derived: sum of 2 quarters · filed 2026-08-06 | $8.13M 10-Q · filed 2025-11-06 | $10.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $2.71M 10-Q · filed 2026-08-06 | $5.42M 10-Q · filed 2026-08-06 | $8.13M derived: sum of 3 quarters · filed 2026-08-06 | $10.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $2.71M 10-Q · filed 2026-05-07 | $5.42M derived: sum of 2 quarters · filed 2026-05-07 | $8.13M derived: sum of 3 quarters · filed 2026-05-07 | $10.84M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.42M derived: sum of 2 quarters · filed 2026-03-02 | $8.13M derived: sum of 3 quarters · filed 2026-03-02 | $10.84M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $2.71M 10-Q · filed 2025-11-06 | $5.42M derived: sum of 2 quarters · filed 2025-11-06 | $8.13M 10-Q · filed 2025-11-06 | $10.84M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | $2.71M 10-Q · filed 2025-08-07 | $5.42M 10-Q · filed 2025-08-07 | $8.13M derived: sum of 3 quarters · filed 2026-03-02 | $10.84M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | $2.71M 10-Q · filed 2025-05-08 | $5.42M derived: sum of 2 quarters · filed 2026-03-02 | $8.13M derived: sum of 3 quarters · filed 2026-03-02 | $10.84M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.42M derived: sum of 2 quarters · filed 2026-03-02 | $8.13M derived: sum of 3 quarters · filed 2026-03-02 | $10.84M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $2.71M 10-Q · filed 2024-11-08 | $5.42M derived: sum of 2 quarters · filed 2024-11-08 | $8.13M 10-Q · filed 2024-11-08 | $10.84M derived: sum of 4 quarters · filed 2025-03-06 | |
| 2023-06-30 | $2.71M 10-Q · filed 2024-08-08 | $2.71M 10-Q · filed 2025-08-07 | $5.42M 10-Q · filed 2023-08-08 | $8.13M derived: sum of 3 quarters · filed 2025-03-06 | $10.84M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $2.71M 10-Q · filed 2024-05-09 | $5.42M derived: sum of 2 quarters · filed 2025-03-06 | $8.13M derived: sum of 3 quarters · filed 2025-03-06 | $10.84M derived: sum of 4 quarters · filed 2025-03-06 | |
| 2022-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $5.42M derived: sum of 2 quarters · filed 2025-03-06 | $8.13M derived: sum of 3 quarters · filed 2025-03-06 | $10.84M 10-K · filed 2025-03-06 | |
| 2022-09-30 | $2.71M 10-Q · filed 2023-11-09 | $5.42M derived: sum of 2 quarters · filed 2023-11-09 | $8.13M 10-Q · filed 2023-11-09 | $8.68M derived: sum of 4 quarters · filed 2024-03-06 | |
| 2022-06-30 | $2.71M 10-Q · filed 2023-08-08 | $5.42M 10-Q · filed 2023-08-08 | $5.97M derived: sum of 3 quarters · filed 2024-03-06 | $5.97M derived: sum of 4 quarters · filed 2024-03-06 | |
| 2022-03-31 | $2.71M 10-Q · filed 2023-05-09 | $3.26M derived: sum of 2 quarters · filed 2024-03-06 | $3.26M derived: sum of 3 quarters · filed 2024-03-06 | $3.26M derived: sum of 4 quarters · filed 2024-03-06 | |
| 2021-12-31 | $550.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $550.00K derived: sum of 2 quarters · filed 2024-03-06 | $550.00K derived: sum of 3 quarters · filed 2024-03-06 | $550.00K 10-K · filed 2024-03-06 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |